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Abstract 
 
 
Context: 
Recessive mutations in TMEM38B cause type XIV osteogenesis imperfecta (OI; OMIM 
611236) by dysregulating intracellular calcium flux.  
Objectives:  
Clinical and bone material phenotype description and osteoblast differentiation studies. 
Design and Setting:  
Natural history study in paediatric research centres. 
Patients:  
Eight patients with type XIV OI. 
Main Outcome Measures:  
Clinical examinations included; bone mineral density, radiographs, echocardiography and 
muscle biopsy. Bone biopsy samples (n=3) were analysed for histomorphometry and 
bone mineral density distribution by quantitative backscattered electron microscopy and 
Raman microspectroscopy. Cellular differentiation studies were performed on proband 
osteoblasts and normal murine osteoclasts. 
Results:  
The clinical phenotype of type XIV OI ranges from asymptomatic to severe. Previously 
unreported features include vertebral fractures, periosteal cloaking, coxa vara and 
extraskeletal features (muscular hypotonia, cardiac abnormalities). Proband L1-L4 bone 
density Z-score was reduced (median -3.3 [range -4.77 to +0.1; n=7]), and increased by 
+1.7 (1.17 to 3.0; n=3) following bisphosphonate therapy. TMEM38B mutant bone has 
reduced trabecular bone volume, osteoblast and particularly osteoclast numbers, with 
>80% reduction in bone resorption. Bone mineralization density is normal/slightly 
increased. We demonstrate a complex osteoblast differentiation defect with decreased 
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expression of early markers and increased late, mineralisation-related markers. 
Predominance of TRIC-B over TRIC-A expression in murine osteoclasts supports an 
intrinsic osteoclast defect underlying low bone turnover. 
Conclusions: OI type XIV has a bone histology, mineralization and osteoblast 
differentiation pattern that is distinct from type I OI. Probands are responsive to 
bisphosphonates but show muscular and cardiovascular features possibly related to 
intracellular calcium flux abnormalities. 
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INTRODUCTION 
Osteogenesis Imperfecta (OI) is a clinically and genotypically heterogeneous, heritable 
connective tissue disorder which results in fragile, deformed bones, short stature and low 
bone mass1. Most cases of OI are due to dominantly inherited mutations in COL1A1 or 
COL1A2 which affect the structure or quantity of type I collagen (Types I-IV)2 3. Rare, 
mostly recessive, forms of OI are caused by defects in genes whose products are involved 
with collagen folding or post-translational modification2 4-7.  
 
Recessively inherited mutations in the TMEM38B gene (OMIM#611236), which encodes the 
ubiquitously expressed ER protein Trimeric Intracellular Cation channel type B (TRIC-B), 
cause OI type XIV (OMIM #615066). TMEM38B mutations reported to date include an exon 
4 deletion among Bedouins8 9, an exon 1-2 deletion in an Albanian child10 and two point 
mutations in exon 4 and intron 3 in three Chinese children11. Using primary fibroblasts and 
osteoblasts from affected individuals, we recently demonstrated that absence of TRIC-B 
disrupts ER calcium flux kinetics, consistent with increased activation of the PERK/ATF4 
pathway of ER stress12. Expression of multiple genes for collagen-interacting proteins is 
altered in proband cells, leading to dysregulated type I collagen synthesis, including 
decreased hydroxylation of collagen helical lysine residues and intracellular retention of 
misfolded collagen13. The full clinical and skeletal phenotype, bone histomorphometry, bone 
material properties, osteoblast differentiation pattern and response to bisphosphonate (BP) 
therapy have not previously been presented. 
 
MATERIAL AND METHODS 
Clinical Data, Samples and Bone Imaging 
Clinical information and anthropometric data were taken from medical records of six patients 
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(P1-6) with genetically confirmed type XIV OI attending OI specialist clinics at Birmingham 
&KLOGUHQ¶V+RVSLWDO (BCH), UK; two brothers (P7,8) were studied at the NIH Clinical Center, 
Bethesda, MD, USA. At BCH and NIH, all patients with clinical signs suggestive of OI are 
offered genetic testing using a µGR you mean targeted exome  OI gene panel. Blood, bone 
biopsy and DNA samples were collected from the patients and their parents after obtaining 
informed consent/assent. Bone densitometry, including lateral vertebral assessment (Hologic 
or *(/XQDUL';$, and X-rays were taken as part of routine clinical care or OI natural 
history protocols. Lateral vertebral morphometry was assessed using the Genant score14. 
 
Bone tissue characteristics: Bone Histomorphometry, quantitative Backscattered Electron 
Imaging (qBEI) and Raman Microspectroscopy 
Trans-iliac bone biopsies were taken in patients 2, 4 and 7 (when naïve to BP therapy) and 
repeated in P7 after one year of BP therapy. Double-labeling with tetracycline for dynamic 
measurement of bone formation was performed in P2 and P7. Sample preparation and 
histomorphometric analyses were performed using standard procedures15. Bone 
mineralisation density distribution (BMDD), reflecting the calcium content of bone matrix, 
was measured in trabecular and cortical bone by qBEI as described previously16.  
Raman microspectroscopy was used to evaluate the properties of the trabecular bone mineral 
and organic matrix as a function of 4 tissue ages17 18: i) between the 2nd fluorescent label and 
the mineralizing front (1-3 day-old bone), ii) between the two fluorescent labels (4-20 day-
old bone), iii) immediately behind the 1st fluorescent label (over 20 day-old bone), and, iv) 
the geometrical centre of trabeculae (older bone tissue). At each tissue age, the 
mineral/matrix ratio, nanoporosity (a surrogate of tissue water), glycosaminoglycan, lipid and 
pyridinoline content were determined, as previously described18. Results from bone 
histomorphometry, qBEI and Raman analysis were compared to paediatric reference data 
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from healthy subjects, and type I OI patients17 19-23. 
 
Molecular Studies 
Genomic DNA was extracted using standard protocols. For P1-6, clonal sequencing using 
SureSelect target enrichment (Agilent Technologies) and the Illumina MiSeq platform was 
performed using a custom designed gene panel. Sequence analysis using a custom 
bioinformatics pipeline based on open source workflow by the Broad Institute 
(http://www.broadinstitute.org/gatk/guide/best-practices) was undertaken using a minimum 
threshold of 30-fold read depth for exonic sequence and intron/exon boundary. Variants 
identified were filtered against polymorphism lists and assessed using the Association for 
Clinical Genetic Science Best Practice Guidelines (http://www.acgs.uk.com). For P7 and P8, 
the maternal TMEM38B mutation was detected by NGS using a recessive OI panel (CTGT, 
Allentown, PA, USA). Subsequently, the paternal mutation was detected by deletion 
analysis13. 
 
Cell Culture 
Primary osteoblast (OB) cultures were established from surgical bone chips of normal control 
and P7, as previously described24. To induce osteoblast differentiation, confluent cells were 
cultured for 30 days in DMEM, supplemented with 10% fetal bovine serum, 1% pen-strep, 25 
ȝJP//-ascorbic acid, 10í8 M dexamethasone and 2.5 mM 2-glycerophosphate.  
Bone marrow-derived primary osteoclast (OC) cultures were generated from femora of 8-
week BL/6 mice as previously described25. Cultures were assessed for an OC phenotype by 
the presence of multinucleated Tracp5-positive stained cells (Sigma). 
 
Analysis of Gene Expression 
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Total RNA was extracted from patient OB and mouse OC cultures at the indicated time 
SRLQWV XVLQJ 7UL5HDJHQW 0ROHFXODU 5HVHDUFK &HQWHU DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
protocol, then treated with DNA-free (Life Technologies). Gene transcript levels of cell 
differentiation markers were quantitated by real-time RT-PCR following reverse-
transcription using a High Capacity cDNA Archive Kit and Taqman Assays on Demand 
(Suppl. Information 1). Relative expression of genes of interest was measured in triplicate 
and normalized to 2 reference genes (ACTB, B2M, Actb, and B2m).  
 
RESULTS 
Molecular Studies 
P1-6 originated from three apparently unrelated Pakistani families seen in our centre or 
something similar and presented with increased bone fragility and osteoporosis. Sanger 
sequencing confirmed that all probands were homozygous for the same c.507G>A mutation 
in exon 4 of TMEM38B. This mutation replaces tryptophan169 with a STOP codon 
(p.W169X). All obligate carrier parents were heterozygous for the mutation (Suppl. Figure 
1). 
P7 and P8 were born to unrelated American parents of British/Scottish and British/German 
origin and found to be compound heterozygous for the previously reported deletion 
encompassing TMEM38B exons 1 and 210 and a novel c.63dupT, which directly introduces a 
premature termination codon (p.D22X). Their father carries the deletion and their mother the 
c.63dupT allele. Both genotypes lead to a TMEM38B null molecular outcome in fibroblast 
and osteoblast (OB) cultures of our patients13. 
 
Clinical and Radiological Phenotype  
Penetrance of clinical OI features was highly variable (Table 1). P1 and P6 presented 
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antenatally with bowed femora. P1-7 had sustained a significant low trauma fracture by 2 
years of age, whilst P8 had no fractures. Two individuals were short (height < -2 SDs) and 
overweight. P5 had non-progressive bilateral nephrocalcinosis of unknown origin detected at 
birth. P7 has relative macrocephaly (58cm, 98th centile) with normal brain MRI, facial 
appearance and dentition. His clinical OI phenotype was severe whilst his brother (P8) was 
asymptomatic. All had normal calcium and phosphate metabolism, only P2 had consistently 
elevated alkaline phosphatase (ALP) levels. 
 
Cognitive Development 
P1 and P2 developed motor skills appropriately but have delayed speech and language 
development. P2 has a concomitant diagnosis of autistic spectrum disorder. Cognitive 
development is normal in P3-8. 
 
Radiological Findings 
Long bone radiographs of all patients demonstrated low bone mass (Suppl. Figure 2). P1,2,4 
and 6 required femoral rodding (Table 1). Interestingly, P1 whose radiographs at birth 
showed femoral bowing with mid-shaft cortical thickening, developed widespread periosteal 
reactions µFORDNLQJ¶RIDOOORQJERQHVDWPRQWKVRIDJH$IROORZ-up skeletal survey at 22 
months of age showed resolving periosteal reaction, coxa vara and low bone mass (Suppl. 
Figure 2 A-C, E, F, H, I). In contrast, P7 has extremely thin long bones (Suppl. Figure 2 N, 
O). P1 had 4-5 Wormian bones around the lambdoid suture at age 2 months.  
 
Spine and Respiratory 
P1 had multiple vertebral compression fractures at age 2 months which showed incomplete 
reshaping by 22 months (Suppl. Figure 2 A, D, G). P2 had multiple vertebral compression 
fractures at presentation aged 12 years (Suppl. Figure 2 J). To date, four patients (50%) have 
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developed scoliosis, which is progressive and deforming in P5 and P7 and led to spinal 
rodding of P5 at age 15 years, following which he has severe restrictive lung disease. P7 
developed moderate lower airway obstruction with air trapping at age 22 years (Table 1). 
 
Cardiovascular Health 
Three patients (P3,5,7) displayed cardiac pathology. P3 presented aged 14 years with 
secondary amenorrhea, significant weight gain (BMI 32kg/m2) and hirsutism. She had 
impaired glucose tolerance (120 min glucose 10.4mmol/L post oral glucose load), acanthosis 
nigricans, and fatty liver on ultrasound. She was started on metformin and later on a 
combined ethinylestradiol/cyproterone acetate contraceptive pill (COCP), on which her 
hirsutism, weight gain and periods improved. Aged 16 years, she had an extensive anterior 
myocardial infarction secondary to a thrombus in the left anterior descending coronary artery. 
Her COCP was discontinued. P5 had a large congenital secundum atrial septal defect and a 
perimembraneous ventricular septal defect. He developed heart failure, requiring surgery 
aged 2 months. 3¶VHchocardiogram aged 21 years revealed tricuspid regurgitation with an 
anatomically normal valve. At age 27, asymmetric septal hypertrophy of the left ventricle and 
mild aortic root dilation were detected. Cardiovascular lipid profile was normal in all eight 
individuals. Echocardiogram and ECG were normal in P1,2,4-6,8. 
 
Muscle Phenotype 
P1-3 and P6, their unaffected siblings, and P7 and P8 have no evidence of myopathy. P4 has 
muscular hypotonia, which was fully investigated. Her EMG showed a denervating pattern 
with no suggestion of muscle myopathic activity. Muscle biopsy also showed no evidence of 
congenital myopathy, metabolic or storage disorder or mitochondrial cytopathy. Serum 
lactate, basic mitochondrial DNA screen and MRI brain were normal. She walks upright with 
a Trendelenburg gait. Her brother, P5, also has moderate hypotonia associated with delayed 
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motor milestones, and only walked without support at 3 years of age.  
 
Clinical and radiological phenotype of heterozygous carriers 
Parents of affected patients had no history of fractures, were generally healthy, with normal 
bone density (BMD) where measured (Z-scores: 0.7 to -0.3, n=4). Parents of P7/8 were fully 
assessed. Their father, age 59 years, has macrocephaly (59cm, >95th centile), moderate hip 
laxity, degenerative changes in mid-thoracic vertebrae, normal BMD (Z-score +0.1), and 
occupational high-frequency hearing loss bilaterally. Echocardiogram shows concentric left 
ventricular hypertrophy, mildly dilated ascending aorta, and mild mitral and aortic 
regurgitation with normal valvular anatomy. Their mother, age 56 years, has type I DM and 
Graves Disease, short stature and normal head circumference. Radiographs show mild central 
compressions of lower thoracic and lumbar vertebrae, with normal BMD (Z-score -0.3). 
Calcifications were noted in the abdominal aorta on X-rays, with annular calcification of 
mitral and aortic valves. She has mild mid-frequency sensorineural hearing loss bilaterally. 
 
Bone mineral density and response to BP treatment 
Proband lumbar spine BMD Z-scores varied widely, ranging from normal (P3,4) to 
osteopenic (P6,8) to decreased (P2,5,7 with mean median Z-score -3.3 [range -4.77 to -
2.0]) in individuals old enough to be measured (P2-8, Table 2). Four patients were 
treated with BPs. DXA scans before and after treatment (n=3) revealed substantial 
increase in BMD Z-score of 3, 1.7 and 1.17 SD (median +1.7), respectively. Patients with 
BMD Z-scores within the normal range have not required BP treatment to date. 
 
Evaluation of trans-iliac bone biopsies 
A) Bone histomorphometry (Table 3) 
The main histomorphometric features in the trans-iliac biopsy samples (P2,4,7) were 
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predominance of low bone mass, normal to reduced OB numbers and very low resorption. 
Backscattered electron images demonstrate bone volumes (BV/TV) below -1SD in P4 
(Figure 1C) and below -4SD (-82% from normal) in P7 (Figure 1D).  Whilst BV/TV could 
not be assessed in P2, many thin and partially isolated trabecular features were viewed in the 
cancellous compartment (Figure 1A, B). Trabecular surfaces (in P2 and P7) were covered by 
an abnormally extended and thin osteoid layer resulting in a substantial increase in osteoid 
surface (OS/BS) and osteoid volume (OV/BV) (Table 3). Unlike OI caused by collagen-gene 
mutations, neither OB nor OC indices were increased in affected patients. In fact, OB surface 
(Ob.S/BS) and mineralizing surface (MS/BS) were within normal range or decreased (P4). 
Interestingly, despite the low amount of trabecular bone, intense fluorescent double labels 
were detected in cortical bone (Figure 1E, P7). P2 had focal areas of osteoid accumulation 
which explains the elevated mineralization lag time (Mlt) and the low adjusted apposition 
rate (aj.AR). In all patients, OC and bone resorption indices were markedly decreased to less 
than 20% of healthy controls. Bone cortex had a normal thickness, lamellar pattern, and 
normal haversian canals.  
 
B) qBEI (Table 4) 
Trabecular bone: 
In P2 and P7, the average bone matrix mineralization was normal, rather than elevated as in 
OI type I bone. The matrix portion with low mineralization (CaLow) was slightly above both 
the healthy reference and OI type I ranges. In contrast, P4 had a BMDD curve that was 
shifted towards higher matrix mineralization (Figure 1F) with increased CaMean, CaPeak 
and CaHigh values, consistent with low turnover revealed on histomorphometry. In all 
patients, the portion of fully mineralized CaHigh was markedly lower (53-84%) than in OI 
type I.  
Cortical bone: 
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The CaMean and CaPeak of P2 and P4 were within the normal range, although again P4 
showed increased CaHigh. ,Q FRQWUDVW 3¶V FRUWLFDO ERQH matrix before BP treatment was 
much less mineralized than control bone, even less than his trabecular bone (CaMean: -7%, 
and -10% respectively). Concomitantly, there was a 3-fold increase of CaLow reflecting the 
large portion of bone undergoing primary mineralization. The high cortical bone apposition 
was mirrored by strong tetracycline labeling on endo ±and intracortical surfaces (Figure 1E). 
After one year of BP therapy, his cortical CaMean and CaPeak increased and CaLow 
decreased substantially, reflecting increasing tissue age due to the anticatabolic therapy.  
 
C) Raman Microspectroscopy 
Mineral/matrix and mineral maturity/crystallinity ratios were within reference range of 
healthy children. Nanoporosity was decreased (at younger tissue ages in P2,7 and oldest in 
P4), compared to healthy controls and even lower than classical OI bone. Relative 
glycosaminoglycan content at the oldest tissue age was decreased in P2,4 and increased in P7 
compared to healthy children. Lipid content was lower in P2 and P7 compared to healthy 
children. Finally, pyridinoline content was comparable to OI type I bone, being higher than 
normal at the two younger tissue ages, and normal at older ones (Suppl. Table 5). 
 
Osteoblast and osteoclast studies 
Cultured osteoblasts from P7 showed reduced expression of early markers of differentiation 
(RUNX, SP7, COL1A1, SPARC), an increase in later markers, including those related to 
mineralisation (ALP, OPN, IBSP, BGLAP, DMP) and also delayed SOST expression (Figure 
2). The normal RANKL/OPG profile suggests normal functioning of the major extrinsic OC 
stimulation system. To explain the low bone resorption on patient bone histomorphometry, 
we examined osteoclasts from murine cultures, since cultures of patient osteoclasts were not 
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available. We determined whether Tric-b and its coupled [Ca2+] channel Itpr3 were expressed 
in differentiated murine osteoclasts, as well as the potential for redundancy by Tric-a and its 
coupled Ryr3 [Ca2+] channel in this cell type26. The results confirm marked predominant 
expression of the ER TRIC-B channel over TRIC-A (10-15-fold in mature OC), and the 
IP3R3 [Ca2+] efflux channel over RyR3 (| 25-fold), respectively (Figure 2, bottom panels). 
 
DISCUSSION 
The null mutations in TMEM38B that cause type XIV OI disturb the kinetics of ER calcium 
flux and impact the function of multiple proteins in the ER13. We previously demonstrated in 
TMEM38B-null cells that type I collagen post-translational modification is altered in a 
distinct pattern for OI, with decreased helical and increased telopeptide lysyl hydroxylation 
compared to the helical overmodification that is a hallmark of autosomal dominant classical 
OI and recessive defects in procollagen prolyl 3-hydroxylation. Procollagen in TMEM38B-
null cells is also misfolded and substantially degraded intracellularly, underlying reduced 
collagen secretion. Here, we present our extensive investigations of the type XIV OI 
phenotype, and distinctive bone tissue characteristics and bone cellular defects arising from 
defective ER calcium flux kinetics.  
 
First, the phenotype of our eight probands with TMEM38B null mutations had quite variable 
penetrance, ranging from barely detectable to severe skeletal characteristics. One patient (P8) 
had no fractures, normal height and osteopenia although his sibling (P7) was the most 
severely affected patient in our set. Development of scoliosis and hearing loss was variable, 
and 3 patients had normal height. We also observed previously unreported features such as 
vertebral fractures with spontaneous reshaping, periosteal cloaking, coxa vara and abnormal 
dentition. Periosteal cloaking similar to our observation in P1 appears to be present on 
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radiographs of other patients with OI type XIV8 and in another report of OI of unknown 
etiology27. Such generalised cloaking may represent a response to healing long bone fractures 
and has not been reported in classical OI. Cardiac abnormalities of different etiologies were 
observed in 3/8 patients, and in both carrier parents of P7 and P8. P4 and P5 have muscular 
hypotonia. However, muscle and myocardial cells express much more TRIC-A than the 
ubiquitous TRIC-B28, although TRIC-B deficiency may indirectly affect these tissues via 
increased ER stress. Tric-a and Tric-b double KO mice die in-utero due to cardiac arrest, 
indicating a shared role of these channels in Ca2+ signalling in embryonic cardiomyocytes. In 
addition, even Tric-b +/- mice are susceptible to stress-induced heart failure28, which 
potentially puts the cardiac findings of 3¶V heterozygous parents in a different light. Until 
more evidence becomes available, monitoring cardiovascular risk factors in affected patients 
may be required. In addition, the lack of significant respiratory abnormalities in our patients 
contrasts the Tric-b KO mouse model which shows respiratory defects with abnormal IP3R-
mediated Ca2+ release in airway epithelial cells. Finally, in view of parental consanguinity, 
we cannot confidently attribute cognitive impairment in P1 and P2 to a TMEM38B effect in 
neuroepithelial tissue.  
 
OI type XIV bone is structurally distinct from bone with type I collagen gene defects. In the 
absence of TRIC-B, bone tissue has low-normal OB numbers with a low mineral apposition 
rate (Aj.AR) and a uniform paucity of OCs.  In classical OI, even simply with type I collagen 
haploinsufficiency, bone turnover and cell numbers are high, but mineral apposition rate is 
low, implying that many OBs produce a reduced amount of matrix19, which is typically 
hypermineralized15. BMDD by qBEI in TRIC-B deficient bone is either normal or slightly 
right-shifted, reflecting a situation of low bone turnover that allows more time for bone 
packets to mineralize16 29. Specifically P4 has a high mineralization, low turnover profile 
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similar to children with chronic kidney disease30. In contrast, bone from P7, with the most 
severe skeletal phenotype, featured active OBs on rudimental trabeculae, a lack of OCs but 
normal BMDD. Strikingly, his cortex showed active primary bone formation as evidenced by 
intense intra- and endocortical fluorescence labeling (Figure 2E) and increased cortical 
CaLow. Raman microspectroscopic analysis also revealed that the ratio of mineral to matrix 
was not altered in TMEM38B mutant bone. However, similar to classical OI bone, 
nanoporosity, a surrogate of tissue water, was decreased at the three younger tissue ages 
compared to healthy controls22. Consistently, the elevated pyridinoline content at the two 
younger tissue ages mirrors increased or accelerated trivalent cross-links formation resulting 
in stiffer collagen fibersZKLFKDUHNQRZQWRH[KLELWDPRUH³brittle-OLNH´behavior31. Thus, 
bone fragility in type XIV OI is explained by low bone mass, reduced trabecular bone and 
nanoporosity, and high pyridinoline content. Despite low bone resorption, bone mass and 
cortical mineralization density increased in response to BP therapy in Type XIV OI patients. 
The observed shift towards higher, and less heterogeneous, cortical BMDD following one 
year of BP therapy is characteristic for patients with normal or lowered mineralization 
density16. This is again in sharp contrast to classical OI bone where the hypermineralized, 
fully saturated matrix cannot further increase its density32.  
 
Differentiation of osteoblasts derived from iliac crest of a TMEM38B-null proband 
demonstrated reduced expression of RUNX2, SP7, and COL1A1. Decreased expression of 
these early markers of differentiation is consistent with the reduction in OB numbers shown 
on bone biopsy in our patients, and would exacerbate the decreased collagen secretion 
resulting from collagen misfolding in the ER13.  Expression of the OB differentiation marker 
ALP is related to calcium flux since its suppression by siRNA blocks BMP2-induced flux of  
[Ca2+] from ER to cytoplasm, raising the proposal of ALP as a monitor of intracellular 
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calcium concentration33. Our cell culture work suggests that this loop may also work in the 
reverse direction, with reduced ER calcium flux in TRIC-B deficient cells leading to a 
compensatory increase in osteoblast ALP expression.  
     
 Ca2+ signalling also has broad effects on pathways promoting and inhibiting mineralization. 
Interestingly, expression of multiple genes whose products interact with calcium and/or have 
roles in mineralization are altered in Type XIV OI osteoblasts, although mineralization of 
type XIV OI bone tissue is not abnormal. On the one hand, expression of pro-mineralization 
ALP34 is increased. On the other hand, there is decreased expression of osteonectin/SPARC, 
which initiates and promotes mineralization, and increased osteocalcin/BGLAP and OPN, 
which inhibit crystal growth35 36. The SIBLING proteins BSP and OPN have generally 
opposing roles in promoting and opposing mineralization37, but their concurrent increase in 
transcripts in TRIC-B deficient cells is unexpected, since BSP-/- cells have increase OPN 
expression38. Further, SOST expression was delayed, suggesting differentiation to osteocytes 
may be impaired. The complex OB gene expression pattern apparently contravenes the usual 
OI mechanism toward hypermineralization. Studies on the levels and interactions of these 
proteins in TRIC-B deficient cells and matrix should be a focus of further investigation. 
 
A recent report on calvarial osteoblasts of Tric-b KO mice26 is in partial agreement with our 
patient findings. Differentiated KO murine osteoblasts have normal levels of type I collagen 
transcripts, with decreased collagen production due to intracellular degradation. As in patient 
cells, the early OB markers Runx2 and Osx are reduced in murine KO OBs. However, Alp, 
Bsp and Bglap transcripts are reduced, while Sparc is normal, suggesting greater impairment 
of murine OB differentiation and mineralization than in patients. 
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An apparent intrinsic defect in osteoclasts is yet another distinctive feature of Type 
XIV OI. To investigate the low numbers and activity of OC in patient bone in the context of 
normal osteoblast RANKL/OPG ratios, we investigated the levels of expression of the TRIC-
B/IP3R and TRIC-A/RyR paired sets of channels for K+ entry and Ca2+ efflux from the ER in 
normal murine OCs. Our demonstration of 15-fold higher expression of TRIC-B relative to 
TRIC-A, and 25-fold higher expression of IP3R than RyR channels support the predominance 
of the TRIC-B system in osteoclasts, with minimal to no redundancy of function. Combined 
with patient histomorphometry and in vitro OB expression profiles, our data support an 
intrinsic, OB-independent, OC defect in patients with TMEM38B mutations. We speculate 
that interference with [Ca2+] flux kinetics in TRIC-B null OCs impairs their response to 
normal developmental signals, resulting in low OC numbers, and impairing bone resorption. 
In recent experimental data from Tric-b-/- mice26, OC markers such as cathepsin K and 
Atp6v0d2 (part of the proton pump functioning in extracellular acidification for resorption), 
had reduced expression in newborn murine femora.  
 
In conclusion, OI caused by TMEM38B mutations has a much wider skeletal phenotypic 
spectrum than previously reported, ranging from asymptomatic to severe. We describe novel 
skeletal features and potential extraskeletal features. Bone tissue of our patients did not reveal 
the characteristic OI phenotype, with high bone turnover and high BMDD23. While normal 
BMDD has also been reported in OI caused by WNT1 mutations39, WNT1-deficient patients 
lack the abnormalities of type I collagen post-translational modification found in OI type 
XIV. The paucity of OBs and OCs, the normal BMDD, and the very low nanoporosity are 
uniquely different from classical OI bone. Here, we further delineate the mechanism of bone 
fragility in TMEM38B mutant bone not only as a complex OB differentiation defect due to 
impaired ER Ca2+ flux kinetics, but also likely an intrinsic OC defect. Despite the low bone 
 18 
resorption, patients still respond to BP therapy with increased BMD and cortical 
mineralisation density. The role of TRIC-B in human OB and OC function, as well as 
cardiovascular or muscular health requires further study. 
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Figure Legends: 
 
Figure 1: Bone tissue characteristics 
Trans-iliac bone biopsy section of patient 2 under light microscopy (A) shows plump 
osteoblasts forming an unmineralized matrix (dark gray). Mineralized matrix appears light 
JUD\ *ROGQHU¶V WULFKURPH VWDLQLQJ UHSUHVHQWV RULJLQDOO\ PLQHUDOL]HG ERQH PDWUL[ LQ JUHHQ, 
and osteoid in purple). Active bone formation was very rarely sighted. Backscattered images 
show bone biopsy samples from Patient 2 (B), 4 (C) and 7 (D). The very low amount of 
trabecular bone tissue in Patient 7¶VVDPSOHLVconsistent with his severe skeletal phenotype. 
Under confocal laser-scanning microscopy, fluorescent double labels are detected on intra- 
and endocortical bone surfaces (E, see white arrows), which does not reflect high bone 
remodeling but cortical bone apposition. F) Bone Mineral Matrix Density Distribution curves 
of cancellous bone of the 3 patients in relation to pediatric reference values20. 
 
Figure 2: Patient Osteoblast and Murine Osteoclast Differentiation 
Osteoblast differentiation time course (from P7) depicting relative levels of RNA transcripts 
for various proteins involved in collagen synthesis or bone mineralisation, measured at 
baseline and every 5d, for 30d. RNA transcripts included RUNX, SP7, COL1A1, ALPL 
(TNSALP), BGLAP (osteocalcin), SPARC (osteonectin), OPN (osteopontin), IBSP, DMP1, 
SOST and RANKL/OPG. Murine osteoclast differentiation cultures (bottom panels) were used 
to measure calcium channel expressions. Itpr3/Ryr3 are equivalent to the human ER calcium 
efflux channels IP3R and RyR, and Tric-b/Tric-a are equivalent to the human channels TRIC-
B and TRIC-A. 
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Table 1 Clinical phenotype of affected patients 
 
Patient P1 P2 P3 P4 P5 P6 P7 P8 
Sex Male Male Female Female Male Female Male Male 
Antenatal Scan Bowed left 
femur 
Normal Normal Normal Normal Bowed 
femora 
Normal Normal 
Birth weight (kg) at term 2.5 2.7 2.4 2.9 1.8 2.3 3.4 2.64 (34 wks) 
Sclera Grey White White Blue White Blue Blue White 
Age 1st fracture (years) 0.2 2 2 0.3 0.5 0 0 No fractures 
Location 1st recorded fracture  Vertebra Femur Femur Femur Tibia Femur Femur No fractures 
Rodding surgery location (age-
years; number of operations) 
Femur (2.5;1) Femur (6.9;1) None Femur 
(2.5; 1) 
Femur (7;1) 
Spine (12; 
2) 
None Lower limbs 
(2-7; 7) 
None 
Developmental delay Global Global None None Motor Motor None None 
Hearing loss Sensorineural Normal Normal Normal Normal Normal Sensorineural Normal 
Scoliosis Nil Nil Nil Mild Severe Mild Severe Nil 
Height Z score (age, years) -1.07 (4) 0.2 (14.11) -1.9 (22) -2 (22) -1.27 (14.6) -1.2 (11.9) -3 (27) 0.1 (24) 
Weight Z score (age, years) 1.48 (4) 2.6 (14.11) 1.5 (22) 1 (22) 0.01 (14.6) -0.2 (11.9) 0 (27) 1.5 (24) 
BMI Z score 3.07 2.4 1.9 1.7 0.76 0.6 (11.9) 1 1.5 
 24 
Table 2 Bone density, fractures and response to bisphosphonate therapy 
 
 
* lumbar spine QCT density Z-score -2.9 
 
Patient P1 P2 P3 P4 P5 P6 P7 P8 
Current age (years) 3 13.5 25 23 13.5 10 27 24 
Lumbar spine BMD Z-score (age 
in years) 
Too young -3.1 (12) -0.5 (23y) 0.1 (21y) -2.0 (4) -1.6 (5y) -4.77 (12y) * -1.8 (24y) 
Lumbar spine BMD Z-score post-
BP treatment (duration in years) 
N/A -0.1 (2y) N/A N/A -0.3 (6y) N/A -3.6 (1y) N/A 
BP therapy Pamidronate, 
Zoledronate  
Zoledronate None None Pamidronate, 
Zoledronate  
None Pamidronate None 
Age started (years) 2 12 N/A N/A 5 N/A 13 N/A 
Number of vertebral fractures 
(age, years) 
8 (0.2) 13 (11) None None 3 (4) None None Nil 
Number of non-vertebral fractures 
prior to BP treatment (location) 
0 4 (femur) 2 (femur, 
radius) 
 
5 (femur) 
 
5 (tibia, femur, 
humerus) 
2 (femur, 
tibia) 
 
17 (lower 
extremity 
long bones) 
0 
Number of non-vertebral fractures 
after BPs started (location) 
2 (femur, tibia) 0 N/A N/A 1 (tibia) N/A 1 (tibia) 0 
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Table 3 Results of bone histomorphometry 
 
 
 
 
 
 
 
 
Parameters  Control values 15
  
Patient  
2 
Patient 
4 
Patient 
7 
OI type I  
19
 
Age at biopsy 
(years) 11-13.9 12  12  13  7.6 ± 3.8  
Structural parameters 
BV/TV [%]  24.4 ± 4.3 ## 17.98 4.46 11.0 ± 5.2 
7E7K>ȝP@ 148 ± 23 93.43 141.64 53.94 105.0 ± 25 
Tb.N. [/mm] 1.66 ± 0.22 ## 1.27 0.83 1.3 ± 0.39 
Ct. Wi [mm] 0.90 ± 0.33 # 0.81## 0.60 0.56 0.52 ± 0.20 
Static parameters of bone formation 
OV/BV  [%] 2.12 ± 1.0 4.18 1.97 4.73 5.2 ± 2.6 
O.Th [µm] 6.7 ± 1.7 4.55 7.94 3.43 5.5 ± 1.7 
OS/BS [%] 22.1 ± 7.8 54.22 17.23 38.08 48 ± 14 
ObS/BS [%] 6.7 ± 4.5 2.97 0.96 8.98 19.4 ± 9.5 
Dynamic parameters of bone formation 
MS/BS [%] 11.07 ± 5.0 7.05 n.a 9.93 48 ± 16 
MAR [µm/d] 0.87 ±0.09 0.92 n.a 0.77 0.73 ± 0.18 
Aj. AR  [µm/d] 0.46 ± 0.10 0.12 n.a 0.20 0.35 ± 0.14 
BFR/BS [µm/y] 37.3 ± 16.7 23.77 n.a 27.75 77 ± 34 
BFR/BV [%/y] 49.9 ± 21.4 50.28 n.a 108.18 116 ± 62  
Mlt  [d] 14.5 ± 3.00 37.88 n.a 17.18 16.5  [12.5 -19.8] 
Static parameters of bone resorption 
ES/BS [%] 14.9 ± 5.6 2.94 1.55 0 15.6  [13.7 - 21.8] 
Oc.S/BS [%] 1.14 ± 0.74 0.15 0.10 0 1.37   [1.05 - 1.70] 
N. Oc/BS [/mm] 0.29 ± 0.14 0.04 0.03 0 0.47 ± 0.29 
 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For comparison, typical values for patients with OI type I are given 19. # Mean value 
from two cortical plates; ## sample contained only one cortical plate. Therefore BV/TV 
and Tb.N could not be assessed. Patient 4 did not receive tetracycline labeling. 
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Table 4 qBEI results from cancellous and cortical bone 
 
 
BMDD 
parameters: 
Reference values 
Controls 20 P2 P4 P7 # 
P7 post BP 
treatment 
Reference values 
OI type I  
Cancellous bone 
CaMean 
[wt% Ca] 
20.95 
(0.57) 20.67 22.09 21.10 - 
22.43 
(0.63) 
CaPeak 
[wt% Ca] 
21.66 
(0.52) 21.66 22.87 22.36 - 
23.39 
(0.57) 
CaWidth 
>ǻZW&D@ 
3.47 
[3.12; 3.64] 3.64 3.12 2.95 - 
3.08 
(0.28) 
CaLow 
[%] 
6.14 
[4.90; 7.99] 9.65 4.43 9.59 - 
5.94 
(2.05) 
CaHigh 
[%] 
0.89 
[0.43; 1.47] 1.24 3.54 2.03 - 
7.54 
[5.00;11.82] 
Cortical Bone 
CaMean 
[wt% Ca] 
20.45 
[19.68; 21.04] 20.99 21.07 19.04 21.00 
22.51 
(0.46) 
(0.46) 
 
CaPeak 
[wt% Ca] 
21.14 
[20.62; 21.75] 21.66 21.92 19.50 21.49 
23.29 
(0.48) 
- CaWidth 
[ǻwt% Ca] 
3.81 
[3.38; 4.38] 3.29 4.42 5.03 3.81 
3.28 
(0.25) 
 
 
CaLow 
[%] 
9.06 
[6.22; 15.00] 6.53 8.61 27.40 5.32 
4.60 
(0.80) 
- CaHigh 
[%] 
0.46 
[0.28; 1.22] 
0.81 2.33 0.36 0.44 
8.60 
(4.00) 
  
Reference values for controls and OI patients provided as median [interquartile range] 
or mean (SD), as appropriate. 
*Only one cortex available  
# High cortical bone formation 
